美國(guó)NOVABIOS藥篩檢測(cè)試劑盒12聯(lián)卡
Multi DOA Screen Panel are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to fourteen of the following drugs in a variety of combination

         美國(guó)NOVABIOS藥篩檢測(cè)試劑盒12聯(lián)卡

 

我司同時(shí)提供 BZO-BAR-COC-THC -MET--OPI-OXY-MDMA-PCP- AMP-BUP-XTC-MTD 多聯(lián)（膠體金法）

Multi DOA Screen Panel are rapid chromatographic immunoassays for the qualitative and simultaneous detection of one to fourteen of the following drugs in a variety of combinations in human urine. The designed cutoff concentrations and direct calibrator for these drugs are as follows:

美國(guó)NOVABIOS藥篩檢測(cè)試劑盒12聯(lián)卡

 

THC (GC/MS specifications are the value of 11-nor-D⁹-THC-9-COOH): In this study, one hundred twenty-two (122) negative and positive urine samples (0 to >2000 ng/ml) were tested and compared with GC/MS. The concentrations of three discrepant specimens were confirmed with GC/MS to be close to the cutoff value (48, 50 and 54 ng/ml). The results are summarized below:

Positive Agreement: 96.8 % and Negative Agreement: 98.3%

	(-)		(+)
Drug Screen	GC/MS Negative (0 ng/ml to 75%)	Near cutoff negative (75%- cutoff)	Near cutoff positive (cutoff to 125%)	GC/MS Positive (> 125%)	% Agreement with GC/MS
(+)	0	1	7	53	96.8 %
(-)	45	14	2	0	98.3 %
Total	45	15	9	53	97.5 %

 

Parameter	Calibrator	Cut-off(ng/mL)
THC	11-nor-D9-THC-9-COOH	50 ng/ml
COC	Benzoylecgonine	300 ng/ml
PCP	Phencyclidine	25 ng/ml
OPI	Morphine	2000 ng/ml
MET	Methamphetamine	1000 ng/ml
MTD	Methadone	300 ng/ml
AMP	Amphetamine	1000 ng/ml
BAR	Secobarbital	300 ng/ml
BZO	Oxazepam	300 ng/ml
TCA	Nortriptyline	1000 ng/ml
MDMA	3,4-Methylenediioxy-MET	500 ng/ml
BUP	BUP-3-D-Glucuronide	10 ng/ml
EDDP	EDDP	100 ng/ml
OPI/MOR	Morphine	300 ng/ml
KET	Ketamine	1,000ng/ml
TML	Cis-Tramadol	100ng/ml
OXY	Oxycodone	100ng/ml
PPX	Propoxyphene	300ng/ml
K2	JWH-073/JWH-01	50 ng/ml
FYL	*	200 ng/ml
COT	Cotinine	200 ng/ml
ALC	Alcohol

 

The test is used to obtain visual qualitative result and is intended for health care professionals use including professionals at point of care sites to assist in the determination of drug compliance. It is not intended for over the counter sale to non-professionals.

This assay provided only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/ Mass Spectrometry (GC/MS) or Liquid Chromatography/ Mass Spectrometry (LC/MS) are the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

INTRODUCTION

Urine based screening tests for drugs of abuse range from simple immunoassay tests to complex analytical procedures. The speed and sensitivity of immunoassays have made them the most widely accepted method for screening urine for drugs of abuse.

 

The DOA Panels are based on the principle of the highly specific immunochemical reactions of antigens and antibodies, which are used for the analysis of specific compounds in human urine. The DOA Screen Panels are rapid, visual, competitive panel immunoassay that can be used for the simultaneous, qualitative detection of 11-nor-D⁹-tetrahydrocannabinol-9-carboxylic acid, Benzoylecgonine, Phencyclidine, Morphine, Methadone, Methamphetamine, Amphetamine, Barbiturates, Oxazepam, Nortriptyline, MDMA, ，Ketamine，Buprenorphine-3-D-Glucuronide, Tramadol and EDDP in urine. The length of time following drug use for which a positive result may occur is dependent upon several factors including the frequency and amount of drug, metabolic rate, excretion rate, drug half-life, and the drug user’s age, weight, activity and diet. 

添加掃一掃二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【  市場(chǎng)部 】       楊永漢
【】 
【騰訊 】
【公司地址】 廣州市清華科技園健新基地番禺石樓鎮(zhèn)健啟路63號(hào)二期2幢101-103室